Concepedia

Author

Craig Tendler

Janssen (United States)ORCID

Also Known As

C L Tendler, C Tendler, C. Tendler, CRAIG TENDLER, Craig L. Tendler, Craig Tendler, Sepideh Shokrpour

49

Publications

3.6K

Citations

19

H-Index

31

Concepts

All Affiliations

Janssen (United States)Johnson & Johnson (United States)Cornell UniversityNational Institutes of HealthMassachusetts General Hospital
CT

About

Craig Tendler is an author at Janssen (United States) specializing in medicine, immunology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

2.3K

2

Immunology

5

5

579

3

Allergy

2

2

238

4

Cell Biology

2

2

271

5

Health Sciences

1

1

49

Craig Tendler

×

23

Publications

3.4K

Citations

18

H-Index

YearCitations

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

E O’Brien, Nely Wigler, Moshe Inbar,

Annals of Oncology

2004

1.7K

Transactivation of the transforming growth factor beta 1 (TGF-beta 1) gene by human T lymphotropic virus type 1 tax: a potential mechanism for the increased production of TGF-beta 1 in adult T cell leukemia.

S J Kim, John H. Kehrl, J. D. Burton,

The Journal of Experimental Medicine

1990

226

Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer

Alan Keller, Robert Mennel, Vassilis A. Georgoulias,

Journal of Clinical Oncology

2004

209

Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.

Philippe Solal‐Céligny, Éric Lepage, Nicole Brousse,

Journal of Clinical Oncology

1998

206

Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy.

Craig Tendler, Steven J. Greenberg, W. A. Blattner,

Proceedings of the National Academy of Sciences

1990

194

Cytokine induction in HTLV‐I associated myelopathy and adult T‐cell leukemia: Alternate molecular mechanisms underlying retroviral pathogenesis

Craig Tendler, Steven J. Greenberg, J. D. Burton,

Journal of Cellular Biochemistry

1991

119

Pegylated Interferon Alfa-2b Treatment for Patients With Solid Tumors: A Phase I/II Study

Ronald M. Bukowski, Marc S. Ernstoff, Martin Gore,

Journal of Clinical Oncology

2002

118

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

Andrzej Jakubowiak, Kent A. Griffith, Donna Reece,

Blood

2011

89

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

Fadlo R. Khuri, Bonnie S. Glisson, Edward S. Kim,

Clinical Cancer Research

2004

77

Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study

Mauricette Michallet, F. Maloisel, Martine Delain,

Leukemia

2003

70

Page 1